

If any additional payment is required, a check which includes the calculated fee of \$_____ (OFGS Check No. _____) is attached.

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

SUMMARY OF AMENDMENTS

1. ____ If checked, an abstract (an amended abstract) is submitted herewith.
2. ____ If checked, amendment(s) to the drawings are submitted herewith.
3. ☒ If checked, amendment(s) to the specification are submitted herewith.
4. ____ If checked, amendment(s) to the claims are submitted herewith.

AMENDMENT(S) TO THE SPECIFICATION

Please replace the paragraph beginning at page 12, lines 8-17, with the following rewritten paragraph:

2. Testing of elastase inhibitor

200 μ M elastase inhibitor III (MeOSuc-Ala-Ala-Pro-Val-CMK SEQ ID NO: 1 from Calbiochem) when added was administered 30 min before addition of the inducers. The inhibitor was dissolved in DMSO to a concentration of 100 mM. The final concentration of DMSO in the system was 0.2%, and was added to all treatments. In separate experiments, 200 μ M of an elastase inhibitor (CE1037, manufactured by Cortech Inc.) was administered 30 min before addition of the inducers. The inhibitor was dissolved in PBS.

Please insert the sequence listing (preceding the claims) attached hereto as page 18A to the specification.